Classic view of this page
VistaSeq Breast Cancer Panel
Clinical Genetic Test
Help
offered by
Molecular Diagnostic Laboratory
GTR Test Accession: Help GTR000556511.2
INHERITED DISEASEINHERITED DISEASE SUSCEPTIBILITYCANCER ... View more
Last updated in GTR: 2019-05-13
View version history
Last annual review date for the lab: 2024-08-01 LinkOut
At a Glance
Test purpose: Help
Diagnosis; Pre-symptomatic; Risk Assessment
Conditions (16): Help
Familial cancer of breast; Ataxia-telangiectasia-like disorder; Breast cancer, early-onset more...
Genes (19): Help
ABRAXAS1 (4q21.23); ATM (11q22.3); BARD1 (2q35); BRCA1 (17q21.31); BRCA2 (13q13.1) more...
Methods (3): Help
Molecular Genetics - Deletion/duplication analysis: Comparative Genomic Hybridization; Multiplex Ligation-dependent Probe Amplification (MLPA); ...
Target population: Help
Patients with a family history consistent with an inherited cancer …
Clinical validity: Help
Not provided
Clinical utility: Help
Not provided
Ordering Information
Offered by: Help
Molecular Diagnostic Laboratory
View lab's website
Specimen Source: Help
  • Peripheral (whole) blood
  • Saliva
Test Order Code: Help
481319
Informed consent required: Help
Decline to answer
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
How to Order, Lab contact for this test, Contact policy, Test strategy, Test development
Conditions Help
Total conditions: 16
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 19
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 3
Method Category Help
Test method Help
Instrument *
Deletion/duplication analysis
Comparative Genomic Hybridization
Deletion/duplication analysis
Multiplex Ligation-dependent Probe Amplification (MLPA)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Diagnosis; Pre-symptomatic; Risk Assessment
Target population: Help
Patients with a family history consistent with an inherited cancer syndrome
Recommended fields not provided:
Clinical validity, Clinical utility, What is the protocol for interpreting a variation as a VUS?, Are family members with defined clinical status recruited to assess significance of VUS without charge?, Will the lab re-contact the ordering physician if variant interpretation changes?, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
The sensitivity of NGS/MPS is over 99% for the detection of single nucleotide variants, and over 85% for small/large deletions and insertions in the regions analyzed, the sensitivity of MLPA analysis is over 95% for the detection of deletions and duplications of complete exons in the regions analyzed, and the … View more
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No
Recommended fields not provided:
Test Confirmation, Assay limitations, Description of internal test validation method, Citations for Analytical validity, PT Provider, Description of PT method, Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review: Help
Not provided
Additional Information
Reviews:
Suggested reading:
Clinical resources:
Molecular resources:

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.